Director Wu Tong's Team:

When patients fail traditional treatments,the cure rate for salvage transplantation is usually only 20%to 30%,and some patients still lose their lives to disease relapse after transplantation.The advent of new technologies like CAR-T in recent years has brought more hope to such patients,especially with Boren's approach of bridging allogeneic hematopoietic stem cell transplantation after CAR-T remission,which can increase the cure rate of refractory relapsed acute lymphoblastic leukemia(ALL)to 60%to 70%,significantly improving survival for these patients.

Beijing GoBroad Boren Hospital has accumulated rich practical experience in CAR-T bridged transplantation and achieved numerous research results.Unlike patients who receive transplantation after achieving remission through chemotherapy,patients after CAR-T therapy are prone to infections,some still with cytokine release syndrome and/or graft-versus-host disease(GVHD)and cytopenia,posing challenges for subsequent transplantation.Due to the lack of international consensus and guidelines for the different clinical characteristics and transplantation difficulties faced by B-ALL and T-ALL patients after CAR-T therapy,Bo Ren Hospital has charted its own course.Research data show that Bo Ren Hospital's hematopoietic stem cell transplantation team is among the best internationally for CAR-T bridged transplantation treatment of refractory relapsed ALL.Meanwhile,for B-ALL and T-ALL patients,the team has gradually developed a relatively comprehensive and mature system for indications,timing,preconditioning regimens,donor selection,and post-transplant management after CAR-T bridged transplantation,benefiting an increasing number of patients.Now,we face a new challenge-CAR-T bridged transplantation for acute myeloid leukemia(AML),a difficult problem that Bo Ren's transplant team is dedicated to exploring and solving.

Director Tong Chunrong's Team:

Humanized CD19 CAR-T Therapy for Murine CD19 CAR-T Relapsed or Refractory R/R B-ALL

For adults and children with R/R B-ALL who have relapsed or are refractory after treatment with murine CD19 CAR-T,the team applied humanized CD19 CAR-T cell therapy,achieving a remission rate of 68%.Bridging to transplantation after humanized CD19 CAR-T therapy can provide patients in complete remission(CR)with longer-term disease remission.